Rising pharma invests $135 million in Parsippany

SourceDaily Record
Date Published12/05/2014
Author NameWilliam Westhoven
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Ferring Pharmaceuticals
Type of work Manufacturing
If manufacturing, is the company an OEM? Yes
Reshoring category:Transplant
Total number of jobs (added or to be added):375
What product(s) and/or service(s) were outsourced domestically?Manufacturing
Year reshoring announced:2014
Year reshoring implemented or to be implemented:2016
Offshore, work was done:In-house
Domestically, the work will be done:In-house
Capital investment ($):135
$/year of sales of reshored product or service:200
Country(ies) from which reshored:Swaziland
City reshored to:Parsippany
State(s) reshored to:NJ
If relevant, work nearshored to:-
Product(s) reshoredPharmaceuticals
What domestic positive factors made reshoring more attractive?Eco-system synergies, Higher productivity, Manufacturing/engineering joint innovation (R&D)
Find Reshoring Articles